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Abstract 
Objectives 
The World Health Organization (WHO) recommends flexible solid oral dosage forms such as dispersible 
tablet as the preferred formulation for (young) children, especially in developing /low- and middle-income 
countries, LMIC. The aim of this study was to assess experience, perceptions of acceptability, and 
formulation preferences, among 10 oral dosage forms for young children in a sample of end-users in 
Nigeria as an exemplar LMIC. 
Methods   
Using a semi-structured and validated questionnaire, 148 caregivers were surveyed. Acceptability was 
assessed by level of liking using a 3-point Likert scale and ease of administration. Preference was assessed 
from participants’ dosage form of choice. Oral dosage forms assessed were those mentioned in in the 
British National Formulary for children, 2013.  
Results 
The formulation perceived as the most acceptable was the chewable/suckable tablet. However, preference 
was for liquids. Specifically with the dispersible tablet, whilst 89% (n=111) of caregivers of young children 
found it easy-to-administer, only 50% of children liked it.  
Conclusion 
There is a gap between the proposal of dispersible tablet as the preferred dosage form for young children 
and caregivers’ perceptions of acceptability and preference. Educational strategies to increase 
acceptability of dispersible tablets as the preferred formulation for young children would be required. 
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A survey of caregivers of Nigerian children less than 6 years of age to determine the 
experience and perception of acceptability of oral solid dosage forms.  
 
Introduction 
The oral route remains the most widely preferred route of medicines administration (WHO, 
2012; EMA, 2013). For the paediatric population in particular, oral liquid medicines have 
been traditionally preferred for infants and younger children less than 6 years old due to the 
limitations in their safe swallowing of conventional tablets or capsules. However the 
associated shortcomings with oral liquid medicines such as stability problems, difficulties in 
taste masking, safety of excipients in children, and high storage and transportation costs led 
to the proposal of flexible solid oral dosage forms (FSODs) by the World Health Organisation 
(WHO) as the preferred formulations for children (WHO, 2012).  
In 2006, the WHO hosted a group of experts in paediatric formulations from the academia, 
pharmaceutical industry (both innovator and generic), regulators, programme managers 
and implementers with a view to reaching a consensus on the most suitable formulations 
for children, with attention to conditions in developing countries. The group recommended 
FSODs such as dispersible tablets, effervescent tablets, chewable tablets, orodispersible 
tablets and sprinkle capsules as the most suitable dosage forms, particularly for developing 
countries (WHO, 2012, WHO, 2014). In September 2010, the United Nations Children’s 
Fund, UNICEF, Supply Division and the WHO further reiterated the preference of solid 
formulations such as FSODs, with emphasis on the dispersible tablet, that can be 
administered in more than one form, for example, given whole to older children or 
7 
 
dispersed in water or breast milk for ease of administration to younger children, as the most 
suitable, or age-appropriate, formulations for children.  
Technical, economic and clinical considerations led the WHO proposal. The technical 
considerations include lower production costs, chemical stability, and potential absence of 
harmful excipients. Economically, solids, being cheaper to manufacture than liquids, could 
be more affordable for end-users in developing countries without access to health 
insurance. Clinically, considering that these dosage forms have a flexible mode of 
administration, they can be used in different subsets of the paediatric population unable to 
safely swallow conventional oral solids.  
However, a formulation with poor acceptability may have an impact on patient safety, 
therapeutic outcomes, compliance, prescribing practice and ultimately commercial viability 
(Ivanoska et al., 2014; Kozarewicz, 2014). It is important to understand the formulation 
acceptability and preferences of parents/caregivers and children for oral solid dosage forms. 
Unlike adults, where oral solid dosage forms such as tablets or capsules will generally be 
acceptable to the majority of patients, potential paediatric patients from neonates to 
adolescents have differing needs. The qualitative features of formulations, such as form and 
taste, can affect acceptance and the likelihood of effective administration to paediatric 
patients. Moreover, certain practical considerations such as awareness of these age-
appropriate dosage forms, and ease of administration, can profoundly impact the usability 
and acceptability of these formulations in resource-limited settings; and yet related 
knowledge is very limited (Orubu 2016).  
While efforts are being made internationally to increase access to age-appropriate 
medicines for children, FSODs have become increasingly available for children with diseases 
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like malaria and HIV, but the barriers to implementation of FSODs in low resource settings 
are still not well understood.  The acceptability and preference for dosage forms may vary 
widely between different cultural settings, socioeconomic contexts and literacy levels. For 
example, a national survey of medicines administration practices and preferences in 
Tanzania in 2013 demonstrated that forms such as dispersible tablets and granules in 
sachets were unfamiliar. Parents/caregivers and healthcare workers were accustomed to 
crushing portions of adult pills and mixing with water to attain a liquid solution (Adams et 
al., 2013). Similarly, other studies have demonstrated commercial unavailability, or lack of 
awareness of an age-appropriate medicine, forcing end-users to use medicines in ways that 
can affect acceptability and efficacy (Best et al., 2011, Thee et al., 2014).  For instance, 
parents/caregivers may wish to administer dispersible tablets by means other than 
intended, that is, as a normal tablet without any prior dispersion. At the same time, children 
may not directly swallow any given tablet, but decide to keep the tablet in their mouth for a 
period of time thereby using it as an orodispersible tablet. 
Specifically with the dispersible tablet, apart from experiential knowledge of the dosage 
form, there are many other obstacles such as unavailability of safe drinking water to 
disperse tablets, poor palatability, and cost, that impact the acceptability and effective 
administration of dispersible tablets to sick children in resource-limited settings (UNICEF, 
2008; WHO, 2015a). Access to quality (improved) water sources is generally low in 
developing countries (UNICEF, 2008; WHO, 2015a).  Where there is poor access to clean 
water, liquids may be regarded as the dosage form of choice for young children, despite the 
disadvantages mentioned earlier. Poor knowledge of the correct means and method of 
administering the dispersible tablet, appropriate dispensing device, volume of water, rinsing 
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out the dosing device after use also can have an effect on acceptability. In 2012, poor 
understanding of the dispersible tablet was identified as a barrier to their proper use (UN 
Commission on life-saving commodities for women and children, 2012).  
In addition to the capacity to use the formulation as authorised, preference can be 
determined by other factors such as an “overall appeal” (related to medicine presentation, 
or packaging), medicine belief systems, and cost (Ward and Kynvin, 2015, WHO, 2015b). 
While appeal and belief systems are largely subjective, cost is not. In developing countries, 
cost can be a major, though not much studied, driver of both acceptability and preference. If 
offered a choice of several products of the same medicine, a patient or caregiver who pays 
for their medicine out-of-pocket is likely to find the lowest-cost product most acceptable 
and preferred (Ward and Kynvin, 2015).  Literacy levels, access to quality water, and the 
ability to pay for medicines show a rural-urban divide and can influence acceptability and 
preference for medicines. Given the critical role these aforementioned factors play in the 
acceptability and preference for medicines, it is important that the acceptability of FSODs is 
assessed among end-users living in both urban and rural areas in a developing country.  In 
this study, Nigeria was conveniently selected as an exemplar developing country. 
 
Materials and methods 
Study design  
The study was designed as a cross-sectional descriptive survey of parents and caregivers of 
children less than 6 years old for their experience with and perception on acceptability and 
preference among several oral dosage forms for children.    
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Study instrument and validation 
The study instrument was a semi-structured questionnaire divided into three parts 
comprising 13 items (Table 1). Part I collated participants’ demographic information. Part II 
assessed experience with 10 types of paediatric oral dosage forms identified from the British 
National Formulary for children (BNFc), 2014, of which five (dispersible tablets,                  
oro-dispersible tablets, chewable tablets, sprinkle capsules, and multi-particulates in 
sachets) can be regarded as FSODs (Table 1). Part II required participants to indicate which 
of the 10 formulations had been administered in the past three to six months, the 
acceptability of each, and a preferred dosage form for children in each of two age sub-
groups as described in section 2.4.1. Acceptability was assessed as described in section 2.5. 
Pictures of the dosage forms were included in this part to facilitate comprehension. Part III 
was specific for the dispersible tablet and elicited participants’ knowledge of the name of 
the dispersible tablet prescribed, acceptability, ease of preparation, preference, and water 
source for administering medicines. In parts II and III, participants were allowed to make 
free-text comments.  
Questionnaire validation was carried out by vetting and pre-testing. Vetting was performed 
by experienced healthcare professionals – a consultant paediatrician, hospital and academic 
pharmacists – to test appropriateness of the questions. The vetted questionnaire was      
pre-tested on 22 participants for validation: a minimum of 80 % of participants reporting the 
questionnaires as easy to fill was taken to mean good comprehension. Data from this stage 
provided information for modification of the study instrument.    
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Study settings 
Study settings were chosen based on convenience to include urban and rural locations in 
two, out of 37 federating units, in Nigeria (Table 2). The urban setting selected was a 
tertiary-level health facility in metropolitan Lagos, Lagos State The peri-urban location with 
a mix of urban and rural areas was chosen as Bayelsa State; facilities surveyed included 
secondary and tertiary hospitals, schools, community pharmacies and places of worship. 
With more than 85% of its population living in the urban metropolitan Lagos, Lagos State 
can be described as urban; while Bayelsa State with a mix of rural and urban locations can 
be described as peri-urban (Lagos State Government, 2011; Iaquinta and Drescher, 2000).  
Participants 
Inclusion criteria 
Criteria for inclusion were parents/caregivers of children aged 6 months – < 6 years with an 
acute condition (malaria) or a chronic condition (HIV/AIDS) prescribed, respectively, 
branded dispersible artemether/lumefantrine and generic dispersible 
lamivudine/nevirapine/zidovudine and/or co-trimoxazole.  Children who had not been 
weaned were excluded from the study.  Children were stratified into two age-groups: 6 
months - < 2 years (infants and toddlers), and 2 - < 6 years (pre-school children) according to 
the EMA classification (EMA, 2006).  
Sample size 
Sample size was 50 participants per age-group in each study location for a total of 100 per 
location, or 200 for the study. As this was an exploratory study, this sample size was 
considered sufficient (Hertzog, 2008, van-Riets et al., 2010).   In order to overcome 
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recruitment pitfalls, an extra 30-50% was added and 130 – 150 participants were targeted 
per location.  
Socioeconomic classification 
Participants were grouped into an upper and a lower socioeconomic class using a 
combination of highest educational attainment and occupation of the breadwinner (the 
parent or caregiver who primarily provided for the family) (Kehinde et al., 2013). 
Participants whose breadwinner had at least a secondary school education and who were 
working as artisans – hairdressers, fashion designers, etc., or were junior school teachers 
were classified as upper class. Those with at most a primary school education working as 
small-scale traders, labourers or messengers were classified as lower class (Oyedeji, 1985, 
Aronu and Ojinnaka, 2009, Fetuga et al., 2010, Frank-Briggs and Alikor, 2011).  
Criteria for assessing acceptability and preference 
Acceptability was assessed using a 3-point Likert scale of “disliked”, “neither disliked nor 
liked”, or “liked” to indicate level of liking and ease of administration of dosage form rated 
as either “easy” or “difficult” as modified from Bayer, et al., (1988). While palatability was 
not directly assessed, the Likert scale was thought a good proxy for assessing the taste of 
the medicine administered in the study period, and hence of the child’s willingness to take 
the medicine. During questionnaire administration, the researchers were careful to express 
this in a way that conveyed that palatability/taste was implied. The rationale for inclusion of 
ease of administration was the fact that it is listed as an important consideration in the 
development of paediatric medicines, and as a measure of the ability of the end-user to use 
the medicine as intended (WHO, 2012). Dosage forms that were liked by ≥80% of children 
and rated as “easy to administer” by ≥80% of parents/caregivers were considered 
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acceptable. Where the dosage form was either liked by ≥80% of children or rated as “easy to 
administer” by ≥80% of parents/caregivers, the dosage form was considered maybe 
acceptable (acceptable for the parent/caregiver, but not for the child).  
Preference was evaluated from the parent/caregivers’ dosage form of choice in the urban 
setting. For the peri-urban setting, participants were asked to rank the top four most 
preferred dosage forms identified from the urban setting. 
Ethics  
Ethical approvals were obtained before study commenced. Ethical approval was received 
from the Health Research and Ethics Committee of Lagos University Teaching Hospital 
(ADM/DSCT/HREC/1589); and from the Head of Clinical Services at Federal Medical Centre, 
Bayelsa State via an internal memo dated April 8, 2014. Verbal informed consent was 
obtained from participants before questionnaire administration. The purpose of the study 
and what was required of participants were explained in local languages (Yoruba, Ibo, or 
Ijaw, as the case was) or Pidgin English before consent was obtained. Participants in the 
urban area who agreed to partake were rewarded with a pack of noodles.   
Questionnaire administration 
The questionnaires were mostly administered by trained researchers (pharmacy students, 
intern or qualified pharmacists). A few, less than 5%, were self-administered by the 
parents/caregivers. 
Data analysis 
Data was anonymised. The results from part II of the questionnaire that considered all oral 
dosage forms for perceptions on acceptability and preference were aggregated for the 
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urban and peri-urban settings and described as percentages. Dosage forms for which there 
were less than 10 respondents were treated as not common and, thus, were not included in 
the analysis.  Results from part III for the dispersible tablet were analysed for differences 
between study arms (acute vs chronic condition) and settings using the Chi square test. A 
two-tailed p value < 0.05 was considered statistically significant. The results for preference 
for the dispersible tablet was descriptive and expressed as percentages.  
 
Results 
Questionnaire validation was conducted from September 24 – October 20, 2013. All 
respondents (100%, n=22) reported the questionnaires as easy-to-fill. However, from the 
answers recorded it was observed that there were some problems with understanding of 
some of the questions. These questions which included whether the age and gender in part I 
of the questionnaire referred to the child or the parent/caregiver, and issues with easy or 
difficult to administer and preferred dosage form were modified. The modifications allowed 
for parents/caregivers to provide both ages and genders of the child and the 
parent/caregiver. In addition, parents/caregivers were made to give reasons for difficulty in 
administration of the dosage form; and the wording of the question for dosage form of 
choice clarified such that participants chose only one preferred dosage form.  
Questionnaire administration was performed for the urban setting in October 2013, and in 
the peri-urban setting in July, 2014. In the urban setting, it was observed that participants 
had no experiential knowledge of oro-dispersible tablets, so the chewable and oro-
dispersible tablets were combined into a single “chewable/suckable” dosage form, or 
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tablets used in the mouth, category in the questionnaire used for the study in the            
peri-urban setting. This left nine oral dosage forms to be assessed. Similarly, with no            
mini-tablet (2-4 mm in diameter) tablet available at the time of the study, folic acid tablets 
(a widely-known medicine among mothers as it is given out during pregnancy) which is 
actually a medium-sized tablet (≈ 8 mm in diameter) was used as the “closest” example. A 
second modification to the questionnaire used in the peri-urban setting allowed participants 
to rank the four most preferred dosage forms as identified from the survey in the urban 
area.  
Demographics  
The study included 148 children aged 6mo – 6 years and their parents/caregivers in two 
different settings (Table 3). In the urban setting, participants’ socioeconomic class varied 
with the disease condition, being of the upper socioeconomic class for the acute condition 
and of the lower socioeconomic class for the chronic condition. In the peri-urban setting, 
participants were mostly of the upper-socioeconomic class. The median age of 
parents/caregivers was 32 years (range 21 – 63 years). Almost all were mothers of the child. 
Experience, perceived acceptability, and preference for oral dosage forms  
Participants had experience with all nine dosage forms, though a wider variety of dosage 
forms had been administered to children aged 2-<6 years (Figure 1).  
Acceptable dosage forms were the suckable/chewable tablets and liquids, depending on 
age-group. For both age-groups, the suckable/chewable tablet was liked by >80% of children 
to whom it had been administered (Figure 1) and also found easy to administer by >90% of 
parents/caregivers (Figure 2). On the other hand, liquids were less liked by children (70 % of 
children <2 years, and 65% of children 2-<6 years were reported to have liked the liquids 
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administered in the past), while 91% of parents/ caregivers of children aged 2-<6 years old 
found it easy to administer (compared to 76% for children aged 6mo-<2 years).  
The least acceptable dosage form in terms of level of liking was the “mini-tablet” (actually a 
medium-sized tablet in this setting) in children <2 years and the sachet in children aged 2-<6 
years, while in terms of ease of administration, it was the crushed tablet in both age-groups.  
The preferred dosage form was liquid (Figure 3).  
Dispersible tablet: knowledge, perspectives on acceptability and preference 
Participants in the urban setting demonstrated good knowledge of the names of the 
dispersible tablets they had administered to their children, although in some cases they had 
to be prompted to recall the names. This was not the case with the peri-urban area.  
The dispersible table was found to be maybe acceptable in the sample studied (n=111). 
While almost all parents/caregivers in both settings found it easy to prepare (Figure 4), only 
about 50% of the children  were reported to have liked the dispersible tablet that was 
administered in the past (Figure 5).  
When participants in the urban setting were asked if they would prefer all medicines for 
their children to be made as dispersible tablets, majority, 65% (47/72), said “no”. The results 
were the same in the peri-urban setting where liquids were ranked as the dosage form of 
first choice for both age-groups (Figure 3). The major reasons given by parents/caregivers 
for the preference for liquids over dispersible tablets were: “these are sweet; or child likes 
liquids”, and “no further preparation required” (Figure 6).  
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Discussion  
Acceptability of oral dosage forms 
Of all nine oral dosage forms assessed, the chewable/suckable tablet was perceived as the 
most acceptable in both age-groups. The chewable/suckable tablet was better liked than 
liquid which is traditionally considered the de-facto dosage form for children in these age-
groups. As deduced from the free-text comments, the main reason liquid was not liked by 
all had to do with taste: parents/caregivers said children only liked a liquid if it tasted sweet; 
none mentioned bulkiness of the container for liquids, or storage conditions as reasons why 
liquids were not liked, though these were not provided as options. On the other hand, the 
chewable tablet formulation(s) that the caregivers would have administered to their 
children – and which was used as an example during questionnaire administration – was 
chewable vitamin C tablets which do not contain a necessarily unpleasant-tasting API 
(vitamin C has an acidic taste), and is often sweetened and flavoured. This was also the case 
with the example of the “orodispersible” tablet used, Strepsils® lozenges, which again is 
sweetened and flavoured. These two medicines are available as over-the-counter (OTC) 
products and so may not necessarily be considered as medicines in these settings. Thus, 
these results as to liking for the chewable/suckable tablet have some degree of bias.  How 
much of the perceived acceptability depended on taste, and how much depended on the 
view as “not medicines” is not known. However, these results show that the taste of the 
medicine was an important determinant of acceptability, as was expected.  
Somewhat surprisingly, in children less than 2 years old, the chewable/suckable tablet was 
reported as having been administered and as acceptable (well liked). However, there is the 
concern that as teething is only complete by the age of 2 years; there might be possible 
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safety issues with swallowing these dosage forms that are meant to be chewed in this age 
group. No parent/caregiver mentioned issues with this though. The literature on the safety 
of chewable tablets in young children is scant, and there is so far only one review 
establishing the safety of chewable tablets in children above the age of 2 years (Michele et 
al., 2002). The same concern applies for the lozenge used as an example of the oro-
dispersible tablet in this study. 
In terms of ease of administration, the chewable/suckable tablet was the dosage form 
found easiest to administer; with liquids found easy to administer by >80% caregivers only 
to children 2-<6 years old. On the other hand, the crushed tablet was considered the most 
difficult to administer, most probably because of the aversive taste of tablets not meant to 
be administered in this manner.   The crushing of tablets is a common manipulation used to 
facilitate the oral administration of medicines in young children. In this study, the medium 
used for dispersing the crushed tablet for administration to the child was not investigated 
but was most likely water. In this, the results differ from that reported for the 
administration of anti-tuberculosis (anti-TB) drugs to children in South Africa where most 
caregivers, 88% (n=83), who crushed tablets and administered with beverages or food 
reported the crushed tablets as easy to administer (Bélard et al., 2015). However, there are 
issues with crushed tablets dispersed in beverages, food, or water. For example, reduced 
bioavailability had been reported for crushed lopinavir/ritonavir tablets (Best et al., 2011), 
and is suggested for crushed ofloxacin and levofloxacin tablets (Thee et al., 2014). It is 
important, therefore, that the effects of mixing paediatric medicines with food/drinks as 
occurs in practice is studied.  Another issue with the use of crushed tablets dispersed in food 
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might arise if all the food is not given leading to loss of dose, and potentially reduced 
efficacy. 
Oral dosage form preferences 
Parents/caregivers preferred liquid over other oral dosage forms for children less than 6 
years old. These results for preference are similar with that reported for Tanzania where  
there was clear preference for liquids in children less than 2 years (76%, 147/185), while 
caregivers  were divided between liquids (48%, 93/185) and crushed tablets/sprinkled 
capsules (30%, 59/185) for 2-6 year olds (Adams et al., 2013). The results are, however, 
different from that reported for Kenya, where preference was for the dispersible tablet 
formulation of artemether-lumefantrine tablet as opposed to the liquid formulation for the 
same age group (Ogutu, et al., 2014).  
Factors identified from this study as influencing acceptability and preference for oral dosage 
forms were mainly taste and the age of the child or familiarity with the dosage form. Most 
parents/caregivers in their free-text comments reported taste as the main factor influencing 
whether the child readily takes a medicine or not. Taste or palatability is a known 
determinant of acceptability and adherence with prescribed medicines in young children as 
well as of preference (Marriot, 2013; Bryson, 2014). With preference, the age of the child as 
a factor in the dosage form of choice may derive from traditionally-held views and might be 
related to prescribing habits of physicians who may routinely prescribe liquids for young 
children. As the results show, it was indeed the most commonly administered oral 
formulation in the sample surveyed. 
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Dispersible tablets: acceptability, preference, and barriers 
While not as well-liked as the chewable/suckable tablets or liquid, the dispersible tablet was 
perceived as easy to prepare or use in both the urban and peri-urban study locations. With 
an average 89% of participants (99/111) reporting the dispersible tablets as easy to prepare, 
these results are in close agreement with that reported for other developing countries of 
Kenya and Bangladesh. In Kenya, 98% (122/126) of caregivers of children less than 5 years 
old with malaria reported dispersible artemether-lumefantrine tablets as either 
“acceptable” (15%), “simple” (68%), or “very simple” (14%) on a 5-point scale accessing 
difficulty or ease of use, while only 2% found it “difficult” and none found the product “very 
difficult” to use (Ogutu, et al., 2014). The study in Bangladesh reported that most caregivers 
(98%, n=303) followed the correct procedure to dissolve dispersible zinc tablets (Nasrin et 
al., 2005). Together, these results indicate that the dosage form is easy to prepare.  
Despite this, participants included in this study showed some reluctance to reconstitute the 
dispersible tablet. This reluctance, and palatability (as noted in section 3.3 and 4.2) 
constituted barriers to acceptability and preference for the dispersible tablet in these 
settings.  
Participants showed willingness to invest in a source of quality water for administering 
medicines (data not included), as had been reported for another developing country with 
access to water concerns (Adams et al., 2013). 
Limitations 
There were some limitations with this study. Firstly, several of the dosage forms were not 
known to the participants. These were: oro-dispersible tablets, mini-tablets, and sprinkle 
capsules. Thus the researchers had to improvise and used examples that were technically 
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not the dosage forms mentioned for these three. This would have introduced some bias for 
the results for these dosage forms, as had been mentioned. In addition, the dispersible 
tablets administered by parents/caregivers might have differed in their formulation and 
taste-making properties and this would have influenced acceptability by the child. No effort 
was made to match formulation with acceptability (level of liking). 
Secondly, as the study relied on experience, and not on actual dosage form administration, 
the results reflect attitudes which might be different from what the parents/caregivers 
might do in actual practice.  
Thirdly, this study did not assess cost. Participants on ARVs/Co-trimoxazole received their 
medicines for free, and artemether/lumefantrine was subsidised, as such the cost of 
medicines as a factor in acceptability or preference could not be evaluated.  
Conclusion 
There is a gap between the WHO proposal of the dispersible tablet as the preferred 
formulation for young children and end-users’ oral formulation preferences in these settings 
at the time of study. While the dispersible tablet was found easy to administer, 
parents/caregivers preferred liquid formulations for children aged 6mo-<6 years. The major 
reasons for preference for liquids over the dispersible tablet was that the children preferred 
liquids (as these were sweet), and reluctance to prepare the dispersion of tablet for 
administration. These reasons constituted barriers in this setting.   
To overcome these barriers, dispersible tablet formulations should be made to demonstrate 
that the products are suitably taste-masked. To change perceptions and facilitate 
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usage/uptake, educational strategies for parents/caregivers emphasising the benefits of the 
dispersible tablets would be needed.  
Though not studied, it would also be necessary to provide guidance as to the reconstitution 
of dispersible tablets in milk or fluids other than water, as bioavailability could be altered.  
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Table 1 Summary of questionnaire 
Part Questions Specific items Response Type/ Options 
Part 1 Socio-
demographic 
information 
 
Age, gender; highest education level 
and occupation of caregiver (or 
breadwinner1) and relationship of 
caregiver to child. 
Self -completion 
Part 2 (2a) Experience 
with oral 
dosage forms 
 
Level of liking 
Oral dosage forms2: 
i. liquids 
ii. intact tablets, 
iii. chewable tablets*, 
iv. orodispersible tablets*, 
v. dispersible tablets*, 
vi. minitablets, 
vii. crushed tablets 
viii. intact capsules, 
ix. sprinkle capsules*, 
x. “sachets”*3. 
 
Not administered. 
Administered, and: 
 Liked 
 Neither liked nor 
disliked 
 Disliked 
 
Ease of 
administration 
Easy to administer. 
Difficult to administer, 
because: 
 Bad (unpleasant) 
taste 
 Needed an 
administration 
device 
 Long dispersion 
times 
 
29 
 
Preference Closed question, with 
options for comments 
 
 
Part 3 (2b) Use of the 
dispersible 
tablet  
 
 
  
Name of dispersible tablet 
prescribed; 
Closed and open-ended 
 Difficulties during preparation, if 
any; 
Level of liking for the dispersible 
tablet; 
 
 Preference for dispersible tablets. 
 
 
 Water source Tap, bottled, sachet, stream, well Closed question 
Notes:   
1. Where the caregiver is not the person who provides for the family. 
2. As identified from the British National Formulary for children, 2014. 
3. Multi-particulates or powders packed in sachets. 
*     FSODs 
 
 
 
 
Table 2 Study locations in Nigeria 
Study 
stage 
State in 
Nigeria 
Institution(s) Study sites within each  state or 
institution 
30 
 
   Acute arm Chronic arm 
Stage I 
(Pre-test) 
Lagos State Lagos University 
Teaching Hospital 
(LUTH) 
 
(In this stage, patients as well as         
health-care practitioners were 
consulted. The questionnaires were 
filled in by a convenience sample of 
patients). 
 
Stage II 
(Urban) 
Lagos State Lagos University 
Teaching Hospital 
(LUTH) 
Paediatric             
Out-patient (POP) 
Clinic; Children’s 
Emergency 
(Olukoye Ransom 
Kuti Children’s 
Emergency, 
ORKCE);  Ward; 
Children Medical 
Ward (D3) 
 
AIDS Preventive 
Initiative in 
Nigeria (APIN) 
Clinic 
31 
 
Stage III 
(Peri-
urban) 
Bayelsa State Various General Hospital, 
and homes in 
Amassoma in 
Southern Ijaw Local 
Government 
Council; community 
pharmacies, 
homes, schools, 
and a church 
premise in Edepie, 
Amarata, Onopa, 
and Kpansia – 
suburbs of Yenagoa 
Local Government 
Council. 
HIV/AIDS 
pharmacy of the 
Federal Medical 
Centre (FMC) 
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Table 3 Demographic characteristics of participants in stages II and III of the study 
 
Urban 
 
Peri-Urban+  
 
 
Acute Chronic Acute Chronic N 
6 mo. - < 2 years 
     
Number of participants (n) 13 30 12 10 65 
Socioeconomic class, upper (%) 62 33 63 70 
 
      
2 - < 6 years 
     
Number of participants (n) 27 21 16 19 83 
Socioeconomic class, upper (%) 48 43 62 83 
 
     
148 
+ An on-going industrial action in the hospitals and the threat of Ebola at the time the study 
was conducted limited participants numbers.  
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Figures 
Captions 
Figure 1 Experience, and level of liking for oral dosage forms as reported by a sample of 
caregivers of children aged:   (a) 6 mo-<2 year-olds, (b) 2-< 6 year-olds. Though all 9 had been 
administered, intact and sprinkle capsules were not common dosage forms, as were tablets 
in children <2 years. The acceptable dosage form in both age-groups was the 
suckable/chewable tablet which was the only dosage liked by >80% of children to whom it 
had been administered.  
Figure 2. Ease of administration of oral dosage forms as reported by a sample of caregivers of 
children in the age-groups:  (a) 6 mo-<2 years,   (b) 2-< 6 years. The dosage forms perceived 
as easy to administer by ≥80% of caregivers were: (i) the chewable/suckable tablet in both 
age-groups, and (ii) liquid in the 2-< 6 years age-group.  
Figure 3. Oral dosage form preferences for: (a) 6 mo - < 2 year-olds, (b) 2-< 6 year-olds. For 
both age-groups, caregivers chose liquid as the preferred dosage form over the 
chewable/suckable and the dispersible tablets. 
Figure 4. Ease of preparation of the dispersible tablet in a sample of caregivers of children < 
6 years old  with an acute (malaria) or chronic (HIV/AIDS) condition in an urban (Lagos State) 
and peri-urban (Bayelsa State) setting in Nigeria.  n is the number of participants who have 
administered/used the dosage form.  There was no difference in the ease of preparation of 
the dispersible tablet among study participants, p=0.95. 
Figure 5. Level of liking for the dispersible tablet as reported by caregivers of children < 6 
years old  with an acute (malaria) or chronic (HIV/AIDS) condition in an urban (Lagos State) 
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and peri-urban (Bayelsa State) setting in Nigeria.  n is the number of participants who have 
administered/used the dosage form. The level of liking for the dispersible tablet was 
independent of disease condition and study setting, p=0.86. 
Figure 6. Reasons given for the choice of liquids as the preferred dosage form for children less 
than 6 years old.   
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Note: n is the number of participants that had administered the dosage form 
Figure 1  
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Note: n is the number of participants that had administered the dosage form. Easy to 
administer is the proportion of participants, %,  who found the dosage form easy to 
administer.  
Figure 2  
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Figure 3  
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Notes:  
1. n = 72.  
2. Other reasons included a combination of child’s liking for liquids and no further 
preparations required before administration of liquids 
Figure 6  
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